RIGL Rigel Corp: רווח נקי למניה ב-12 החודשים האחרונים

Rigel Pharmaceuticals (RIGL) relies on experienced leadership in the field of oncohematology with transparent sales reporting. Business development is based on the commercialization of Tavalisse and new licensing payments. The EPS growth rate over the last 12 months YoY on the GURU.Markets chart reflects profit dynamics, where 166.40 shows the current value of the metric. The company's environmental profile complies with safe chemical reagent disposal standards.

To assess the fundamental stability of Rigel Pharmaceuticals (RIGL), investors should track the rolling year trend of net earnings per share. By analyzing the rolling annual EPS growth chart, which measures the percentage change in TTM earnings, one can evaluate cost management efficiency, including the expensive maintenance of the cold chain during the transport of immunological drugs, which critically impacts the business's final margins.